Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1

Nature Communications

Volumn 5, Issue , 2014, Pages

  Fusi, Camilla ^a   Materazzi, Serena ^a   Benemei, Silvia ^a   Coppi, Elisabetta ^a   Trevisan, Gabriela ^b   Marone, Ilaria M ^a   Minocci, Daiana ^a   De Logu, Francesco ^a   Tuccinardi, Tiziano ^c   Di Tommaso, Maria Rosaria ^a   Susini, Tommaso ^a   Moneti, Gloriano ^a   Pieraccini, Giuseppe ^a   Geppetti, Pierangelo ^a   Nassini, Romina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANASTROZOLE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CGRP 8 37; EXEMESTANE; LETROZOLE; N (4 ISOPROPYLPHENYL) 2 (1,2,3,6 TETRAHYDRO 1,3 DIMETHYL 2,6 DIOXO 7H PURIN 7 YL)ACETAMIDE; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR; CALCIUM; CALCIUM CHANNEL; CYSTEINE; NERVE PROTEIN; NEUROPEPTIDE; NITRILE; STEROID; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRIAZOLE DERIVATIVE; TRPA1 PROTEIN, HUMAN; TRPA1 PROTEIN, MOUSE; TRPA1 PROTEIN, RAT;

CANCER; ENZYME ACTIVITY; INHIBITOR; RECOMBINATION; RODENT; SYMPTOM;

ALLODYNIA; ANGIONEUROTIC EDEMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG MECHANISM; DRUG USE; EXPERIMENTAL THERAPY; GRIP STRENGTH; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROGENIC INFLAMMATION; NOCICEPTION; NONHUMAN; PAIN; RAT; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; HEK293 CELL LINE; INFLAMMATION; METABOLISM; PATCH CLAMP TECHNIQUE; SPRAGUE DAWLEY RAT;

MUS; RODENTIA;

ANDROSTADIENES; ANIMALS; AROMATASE INHIBITORS; BEHAVIOR, ANIMAL; CALCIUM; CALCIUM CHANNELS; CYSTEINE; HEK293 CELLS; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NITRILES; PAIN; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; STEROIDS; TRANSIENT RECEPTOR POTENTIAL CHANNELS; TRIAZOLES; TRPC CATION CHANNELS;

EID: 84923335684     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6736     Document Type: Article

References (70)

1. Gibson, L., Lawrence, D., Dawson, C. & Bliss, J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst. Rev. 7, CD003370 (2009).
2. Burstein, H. J. et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28, 3784-3796 (2010).
3. Cuzick, J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11, 1135-1141 (2013).
4. Nabholtz, J. M. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther. Clin. Risk Manag. 4, 189-204 (2008).
5. Connor, C. & Attai, D. Adjuvant endocrine therapy for the surgeon: options, side effects, and their management. Ann. Surg. Oncol. 20, 3188-3193 (2013).
6. Mouridsen, H. T. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr. Med. Res. Opin. 22, 1609-1621 (2006).
7. Crew, K. D. et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J. Clin. Oncol. 25, 3877-3883 (2007).
8. Henry, N. L. et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat. 111, 365-372 (2008).
9. Laroche, F. et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J. Pain 15, 293-303 (2014).
10. Burstein, H. J. & Winer, E. P. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J. Clin. Oncol. 25, 3797-3799 (2007).
11. Presant, C. A. et al. Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin. Breast Cancer 7, 775-778 (2007).
12. Morales, L. et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res. Treat 104, 87-91 (2007).
13. Henry, N. L. et al. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br. J. Cancer 103, 291-296 (2010).
14. Mao, J. J. et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol. Drug Saf. 22, 256-262 (2013).
15. Sestak, I. et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 9, 866-872 (2008).
16. Nilius, B., Owsianik, G., Voets, T. & Peters, J. A. Transient receptor potential cation channels in disease. Physiol. Rev. 87, 165-217 (2007).
17. Clapham, D. E. TRP channels as cellular sensors. Nature 426, 517-524 (2003).
18. Bautista, D. M. et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 124, 1269-1282 (2006).
19. Trevisani, M. et al. 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc. Natl Acad. Sci. USA 104, 13519-13524 (2007).
20. Zhang, X. F., Chen, J., Faltynek, C. R., Moreland, R. B. & Neelands, T. R. Transient receptor potential A1 mediates an osmotically activated ion channel. Eur. J. Neurosci. 27, 605-611 (2008).
21. Bandell, M. et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41, 849-857 (2004).
22. Karashima, Y. et al. TRPA1 acts as a cold sensor in vitro and in vivo. Proc. Natl Acad. Sci. USA 106, 1273-1278 (2009).
23. del Camino, D. et al. TRPA1 contributes to cold hypersensitivity. J. Neurosci. 30, 15165-15174 (2010).
24. Story, G. M. et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112, 819-829 (2003).
25. Bhattacharya, M. R. et al. Radial stretch reveals distinct populations of mechanosensitive mammalian somatosensory neurons. Proc. Natl Acad. Sci. USA 105, 20015-20020 (2008).
26. Geppetti, P. & Holzer, P. Neurogenic Inflammation (CRC Press, 1996).
27. Andersson, D. A., Gentry, C., Moss, S. & Bevan, S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J. Neurosci. 28, 2485-2494 (2008).
28. Sawada, Y., Hosokawa, H., Matsumura, K. & Kobayashi, S. Activation of transient receptor potential ankyrin 1 by hydrogen peroxide. Eur. J. Neurosci. 27, 1131-1142 (2008).
29. Taylor-Clark, T. E., Ghatta, S., Bettner, W. & Undem, B. J. Nitrooleic acid, an endogenous product of nitrative stress, activates nociceptive sensory nerves via the direct activation of TRPA1. Mol. Pharmacol. 75, 820-829 (2009).
30. Materazzi, S. et al. Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1. Proc. Natl Acad. Sci. USA 105, 12045-12050 (2008).
31. Petrus, M. et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol. Pain 3, 40 (2007).
32. Eid, S. R. et al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol. Pain 4, 48 (2008).
33. da Costa, D. S. et al. The involvement of the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold hyperalgesia in persistent inflammation. Pain 148, 431-437 (2010).
34. McGaraughty, S. et al. TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats. Mol. Pain 6, 14 (2010).
35. Obata, K. et al. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J. Clin. Invest. 115, 2393-2401 (2005).
36. Wei, H., Hamalainen, M. M., Saarnilehto, M., Koivisto, A. & Pertovaara, A. Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. Anesthesiology 111, 147-154 (2009).
37. Nassini, R. et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 152, 1621-1631 (2011).
38. Materazzi, S. et al. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers. Arch. 463, 561-569 (2012).
39. Trevisan, G. et al. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res. 73, 3120-3131 (2013).
40. Liu, H. & Talalay, P. Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc. Natl Acad. Sci. USA 110, 19065-19070 (2013).
41. Hinman, A., Chuang, H. H., Bautista, D. M. & Julius, D. TRP channel activation by reversible covalent modification. Proc. Natl Acad. Sci. USA 103, 19564-19568 (2006).
42. Macpherson, L. J. et al. An ion channel essential for sensing chemical damage. J. Neurosci. 27, 11412-11415 (2007).
43. Brone, B. et al. Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol. Appl. Pharmacol. 231, 150-156 (2008).
44. McNamara, C. R. et al. TRPA1 mediates formalin-induced pain. Proc. Natl Acad. Sci. USA 104, 13525-13530 (2007).
45. Andre, E. et al. Cigarette smoke-induced neurogenic inflammation is mediated by alpha, beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J. Clin. Invest. 118, 2574-2582 (2008).
46. Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C. & Bunnett, N.W. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol. Rev. 94, 265-301 (2014).
47. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. Faseb J. 22, 659-661 (2008).
48. Lintermans, A. et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann. Oncol. 22, 1763-1769 (2011).
49. Jin, S. J. et al. The pharmacokinetics of letrozole: association with key body mass metrics. Int. J. Clin. Pharmacol. Ther. 50, 557-565 (2012).
50. Jukanti, R., Sheela, S., Bandari, S. & Veerareddy, P. R. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J. Pharm. Sci. 100, 3208-3222 (2011).
51. Valle, M. et al. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br. J. Clin. Pharmacol. 59, 355-364 (2005).
52. Dai, Y. et al. Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain. J. Clin. Invest. 117, 1979-1987 (2007).
53. Wang, S. et al. Phospholipase C and protein kinase A mediate bradykinin sensitization of TRPA1: a molecular mechanism of inflammatory pain. Brain 131, 1241-1251 (2008).
54. Vergnolle, N. et al. Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat. Med. 7, 821-826 (2001).
55. Dalle-Donne, I. et al. Actin Cys374 as a nucleophilic target of alpha, betaunsaturated aldehydes. Free Radic. Biol. Med. 42, 583-598 (2007).
56. Oballa, R. M. et al. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg. Med. Chem. Lett. 17, 998-1002 (2007).
57. Moran, M. M., McAlexander, M. A., Biro, T. & Szallasi, A. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug Discov. 10, 601-620 (2011).
58. Kennecke, H. F. et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann. Oncol. 18, 45-51 (2007).
59. Sies, H. Role of metabolic H2O2 generation: redox signaling and oxidative stress. J. Biol. Chem. 289, 8735-8741 (2014).
60. Spinelli, O. et al. Pharmacokinetics (PK) of Aromasin ®(exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur. J. Cancer 35, S295 (1999).
61. Desta, Z. et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin. Pharmacol. Ther. 90, 693-700 (2011).
62. Dowsett, M., Cuzick, J., Howell, A. & Jackson, I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a subprotocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br. J. Cancer 85, 317-324 (2001).
63. Kwan, K. Y. et al. TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 50, 277-289 (2006).
64. Nassini, R. et al. The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain 135, 376-390 (2012).
65. Materazzi, S. et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain 3959, 00438-00437 (2013).
66. Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55-63 (1994).
67. Dixon, W. J. Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 20, 441-462 (1980).
68. Doig, J. et al. In vivo characterization of the role of tissue-specific translation elongation factor 1A2 in protein synthesis reveals insights into muscle atrophy. Febs J. 280, 6528-6540 (2013).
69. Trevisan, G. et al. TRPA1 receptor stimulation by hydrogen peroxide is critical to trigger hyperalgesia and inflammation in a model of acute gout. Free Radic. Biol. Med. 72, 200-209 (2014).
70. la Marca, G. et al. Rapid assay of topiramate in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. J. Pharm. Biomed. Anal. 48, 1392-1396 (2008).